Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului
Yüklə 4,39 Mb.
|
- Bu səhifədəki naviqasiya:
- SUBLISTA C2 - P10: PROGRAM NAŢIONAL DE SUPLEERE A FUNCŢIEI RENALE LA BOLNAVII CU INSUFICIENŢĂ RENALĂ CRONICĂ.
- SUBLISTA C2 - P11: PROGRAM NAŢIONAL DE SĂNĂTATE MINTALĂ. SUBPROGRAMUL TRATAMENTUL TOXICODEPENDENŢELOR
| Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________ DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AA10 SIROLIMUS COMPR. FILM. 1 mg RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 1034 |L04AX01| AZATHIOPRINUM* | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ L04AX01 AZATHIOPRINUM COMPR. FILM. 50 mg IMURAN(R) 50 mg THE WELLCOME FOUNDATION LTD.
________________________________________________________________________________ SUBLISTA C2 - P10: PROGRAM NAŢIONAL DE SUPLEERE A FUNCŢIEI RENALE LA BOLNAVII CU INSUFICIENŢĂ RENALĂ CRONICĂ. ______________________________________________________________________________ | 1035 |A11CC03| ALFACALCIDOLUM | Protocol: A007E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC03 ALFACALCIDOLUM CAPS. MOI 0.25 µg ALPHA D3 0,25 µg 0.25 µg TEVA PHARMACEUTICALS SRL
ALPHA D3 0.50 µg 0.50 µg TEVA PHARMACEUTICALS SRL ________________________________________________________________________________
| 1036 |A11CC04| CALCITRIOLUM** | Protocol: A006E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC04 CALCITRIOLUM CAPS. MOI 0.25 µg ROCALTROL 0.25 µg ROCHE ROMANIA S.R.L. ________________________________________________________________________________ ______________________________________________________________________________ | 1037 |A11CC07| PARICALCITOLUM** | Protocol: A005E | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ A11CC07 PARICALCITOLUM SOL. INJ. 5 µg/ml ZEMPLAR 5 µg/ml ABBOTT LABORATORIES S.A. ________________________________________________________________________________ ______________________________________________________________________________ | 1038 |B01AB01| HEPARINUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB01 HEPARINUM SOL. INJ. 5000 ui/ml HEPARIN 5000 ui/ml POLIPHARMA INDUSTRIES S.R.L.
HEPARIN SANDOZ(R) 5000 ui/ml SANDOZ GMBH 25000 UI/5 ml HEPARINE SODIQUE PANPHARMA 5000 ui/ml LAB. PANPHARMA ________________________________________________________________________________ ______________________________________________________________________________ | 1039 |B01AB05| ENOXAPARINUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti - Xa/0.2 ml CLEXANE 2000 ui anti - Xa/0.2 ml 2000 ui LAB. AVENTIS anti - Xa/0.2 ml B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui anti - Xa/0,4 ml CLEXANE 4000 ui anti - Xa/0.4 ml 4000 ui LAB. AVENTIS anti - Xa/0,4 ml
anti - Xa/0.6 ml CLEXANE 6000 ui 6000 ui LAB. AVENTIS anti - Xa/0.6 ml anti - Xa/0.6 ml B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui anti - Xa/0.8 ml CLEXANE 8000 ui 8000 ui LAB. AVENTIS anti - Xa/0.8 ml anti - Xa/0.8 ml B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui anti - Xa/0.2 ml CLEXANE 2000 ui 2000 ui LAB. AVENTIS anti - Xa/0.2 ml anti - Xa/0.2 ml B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui anti - Xa/0,4 ml CLEXANE 4000 ui 4000 ui LAB. AVENTIS anti - Xa/0.4 ml anti - Xa/0,4 ml B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui anti - Xa/0.6 ml CLEXANE 6000 ui 6000 ui LAB. AVENTIS anti - Xa/0.6 ml anti - Xa/0.6 ml ________________________________________________________________________________
| 1040 |B01AB06| NADROPARINUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB06 NADROPARINUM SOL. INJ. 11400 ui AXa/0.6 ml FRAXODI 11400 UI 11400 ui AXa/0.6 ml GLAXO GROUP LTD. anti - factor Xa/0,6 ml B01AB06 NADROPARINUM SOL. INJ. 15200 ui AXa/0.8 ml FRAXODI 15200 UI 15200 ui AXa/0.8 ml GLAXO GROUP LTD. anti - factor Xa/0,8 ml B01AB06 NADROPARINUM SOL. INJ. 2850 ui AFXa/0.3 ml FRAXIPARINE(R) 2850 UI 2850 ui AFXa/0.3 ml GLAXO GROUP LTD. anti - factor Xa/0,3 ml
FRAXIPARINE(R) 3800 UI 3800 ui AFXa/0.4 ml GLAXO GROUP LTD. anti - factor Xa/0,4 ml
FRAXIPARINE(R) 5700 UI 5700 ui AFXa/0.6 ml GLAXO GROUP LTD. anti - factor Xa/0,6 ml
FRAXIPARINE(R) 7600 UI 7600 ui AXa/0.8 ml GLAXO GROUP LTD. anti - factor Xa/0,8 ml ________________________________________________________________________________ ______________________________________________________________________________ | 1041 |B01AB08| REVIPARINUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG ________________________________________________________________________________
| 1042 |B01AB10| TINZAPARINUM** | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B01AB10 TINZAPARINUM SOL. INJ. 10000 u ANTIF. Xa/ml INNOHEP 10000 U ANTIF. Xa/ml LEO PHARMACEUTICAL PRODUCTS
INNOHEP 20000 U ANTIF. Xa/ml LEO PHARMACEUTICAL PRODUCTS
________________________________________________________________________________ ______________________________________________________________________________ | 1043 |B03AC02| COMPLEX DE HIDROXID DE FER (III) SUCROZA | Protocol: A010N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03AC02 COMPLEX DE HIDROXID SOL. INJ./PERF. 20 mg/ml DE FER (III) SUCROZA VENOFER(R) 20 mg/ml VIFOR FRANCE S.A. ________________________________________________________________________________
| 1044 |B03XA01| EPOETINUM ALFA** | Protocol: B010N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA01 EPOETINUM ALFA SOL. INJ. 10000 ui/ml EPREX(R) 10000 UI 10000 ui/ml JOHNSON & JOHNSON D.O.O.
PREUMPLUTA EPREX(R) 1000 UI 1000 ui/0.5 ml JOHNSON & JOHNSON D.O.O.
PREUMPLUTA BINOCRIT 1000 UI/0,5 ml 1000 UI/0,5 ml SANDOZ GMBH EPOKINE 1000 UI/0,5 ml 1000 UI/0.5 ml RENAMED FARMA S.R.L. B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 20000 UI/0,5 ml PREUMPLUTA EPOKINE 2000 UI/0,5 ml 2000 UI/0.5 ml RENAMED FARMA S.R.L.
EPOPHAR 2000 U.I. 2000 UI GULF PHARMACEUTICAL IND. S.R.L. EPREX(R) 2000 UI 2000 ui/0.5 ml JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 2000 UI/1,0 ml PREUMPLUTA BINOCRIT 2000 UI/1,0 ml 2000 UI/1,0 ml SANDOZ GMBH EPOKINE 2000 UI/1 ml 2000 UI/1 ml RENAMED FARMA S.R.L. B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 3000 UI/0,3 ml PREUMPLUTA BINOCRIT 3000 UI/0,3 ml 3000 UI/0,3 ml SANDOZ GMBH
EPREX(R) 3000 UI 3000 ui/0.3 ml JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 40000 UI EPREX(R) 40000 UI 40000 UI JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI EPOPHAR 4000 UI 4000 UI GULF PHARMACEUTICAL IND. S.R.L. B03XA01 EPOETINUM ALFA SOL. INJ. IN SERINGA 4000 UI/0,4 ml PREUMPLUTA BINOCRIT 4000 UI/0,4 ml 4000 UI/0,4 ml SANDOZ GMBH EPOKINE 4000 UI/0,4 ml 4000 UI/0.4 ml RENAMED FARMA S.R.L. EPREX(R) 4000 UI 4000 ui/0.4 ml JOHNSON & JOHNSON D.O.O. B03XA01 EPOETINUM ALFA SOL. INJ. 4000 UI/1 ml EPOKINE 4000 UI/1 ml 4000 UI/1 ml RENAMED FARMA S.R.L. ________________________________________________________________________________
| 1045 |B03XA01| EPOETINUM BETA** | Protocol: B009N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 10000 UI/0,6 ml PREUMPLUTA NEORECORMON 10000 UI/0,6 ml 10000 UI/0,6 ml ROCHE REGISTRATION LTD. B03XA01 EPOETINUM BETA SOL. INJ. IN SERINGA 1000 UI/0,3 ml PREUMPLUTA NEORECORMON 1000 UI/0,3 ml 1000 UI/0,3 ml ROCHE REGISTRATION LTD.
PREUMPLUTA NEORECORMON 2000 UI/0,3 ml 2000 UI/0,3 ml ROCHE REGISTRATION LTD.
PREUMPLUTA NEORECORMON 4000 UI/0,3 ml 4000 UI/0,3 ml ROCHE REGISTRATION LTD.
PREUMPLUTA NEORECORMON 5000 UI/0,3 ml 5000 UI/0,3 ml ROCHE REGISTRATION LTD.
PREUMPLUTA NEORECORMON 500 UI/0,3 ml 500 UI/0,3 ml ROCHE REGISTRATION LTD. ________________________________________________________________________________ ______________________________________________________________________________ | 1046 |B03XA02| DARBEPOETINUM ALFA** | Protocol: B011N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 10 µg/0,4 ml PREUMPLUTA ARANESP 10 µg/0.4 ml 10 µg/0.4 ml AMGEN EUROPE BV B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 100 µg/0,5 ml PREUMPLUTA ARANESP 100 µg/0.5 ml 100 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 15 µg/0.375 ml 15 µg/0.375 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 150 µg/0.3 ml 150 µg/0.3 ml AMGEN EUROPE BV B03XA02 DARBEPOETINUM ALFA SOL. INJ. IN SERINGA 20 µg/0.5 ml PREUMPLUTA ARANESP 20 µg/0.5 ml 20 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 30 µg/0.3 ml 30 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 300 µg/0.6 ml 300 µg/0.6 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 40 µg/0.4 ml 40 µg/0.4 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 50 µg/0.5 ml 50 µg/0.5 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 500 µg/ml 500 µg/ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 60 µg/0.3 ml 60 µg/0.3 ml AMGEN EUROPE BV
PREUMPLUTA ARANESP 80 µg/0.4 ml 80 µg/0.4 ml AMGEN EUROPE BV ________________________________________________________________________________ ______________________________________________________________________________ | 1049 |V03AE02| SEVELAMER** | Protocol: V003D | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ V03AE02 SEVELAMER COMPR. FILM. 800 mg RENAGEL 800 mg 800 mg GENZYME EUROPE BV ________________________________________________________________________________ ______________________________________________________________________________ | 1050 |H05BX01| CINACALCETUM**** | Protocol: H003N | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ H05BX01 CINACALCETUM COMPR. FILM. 30 mg MIMPARA 30 mg 30 mg AMGEN EUROPE B.V.
MIMPARA 60 mg 60 mg AMGEN EUROPE B.V. H05BX01 CINACALCETUM COMPR. FILM. 90 mg MIMPARA 90 mg 90 mg AMGEN EUROPE B. V. ________________________________________________________________________________
| 1051 |N07BB04| NALTREXONUM | | |_______|_______|____________________________________________|_________________|
DCI/DENUMIRE COMERCIALĂ FORMA FARM. __________________________________________________ CONCENTRAŢIE FIRMA ________________________________________________________________________________ N07BB04 NALTREXONUM COMPR. FILM. 50 mg REVIA 50 mg TORREX CHIESI PHARMA GMBH ________________________________________________________________________________ Naltrexone hydrochloride este contraindicată la pacienţii trataţi cu medicamente opioide ______________________________________________________________________________ | 1052 |N07BC02| METHADONUM | | |_______|_______|____________________________________________|_________________|
Yüklə 4,39 Mb. Dostları ilə paylaş:
|